← back to search

Dario Trapani

University of Milan · IT
Area of research
Cancer Research · Economics and Econometrics
Research interest
Research interests include Economic and Financial Impacts of Cancer, Advanced Breast Cancer Therapies, Cancer Immunotherapy and Biomarkers, and Cancer Genomics and Diagnostics.
h-index
44
citations
9,634
works
389
NIH funding
primary concept
Medicine
email

Recent publications

Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials
The Lancet Oncology 2025cited by 34position: middledoi
Current controversies in the use of Oncotype DX in early breast cancer
Cancer Treatment Reviews 2025cited by 11position: middledoi
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment
npj Breast Cancer 2025cited by 4position: middledoi
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer
Cancer Treatment Reviews 2024cited by 22position: middledoi
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022
Annals of Oncology 2024cited by 19position: middledoi
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit
Cancers 2024cited by 4position: middledoi
206P Prognostic role of tumor-infiltrating lymphocytes (TILs) in first-line HER2-positive (HER2+) metastatic breast cancer (BC): A real-world study
ESMO Open 2024cited by 1position: middledoi
WITHDRAWN: Using antibody-drug conjugates for anti-tumor immunity
Elsevier eBooks 2024cited by 0position: middledoi
Immunotherapy for breast cancer: New strategies to enhance the patient selection and overcome therapeutic resistance
Elsevier eBooks 2024cited by 0position: middledoi
Using antibody-drug conjugates for anti-tumor immunity
Elsevier eBooks 2024cited by 0position: middledoi
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment
Research Square 2024cited by 0position: middledoi
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology 2023cited by 793position: middledoi
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
Annals of Oncology 2023cited by 291position: middledoi
Common Sense Oncology: outcomes that matter
The Lancet Oncology 2023cited by 99position: middledoi
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
Cancer Treatment Reviews 2023cited by 46position: middledoi
The immunogram of inflammatory breast cancer
Cancer Treatment Reviews 2023cited by 27position: middledoi
The rise of immuno-oncology in China: a challenge to western dominance?
The Lancet Oncology 2023cited by 17position: middledoi
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases
European Journal of Cancer 2023cited by 12position: middledoi
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification
Annals of Oncology 2022cited by 50position: firstdoi
The Global Landscape of Treatment Standards for Breast Cancer
JNCI Journal of the National Cancer Institute 2021cited by 22position: firstdoi
The ESSO core curriculum committee update on surgical oncology
European Journal of Surgical Oncology 2021cited by 21position: middledoi
Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries
The Lancet 2020cited by 648position: middledoi
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
Annals of Oncology 2020cited by 312position: middledoi
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden
The Oncologist 2020cited by 50position: middledoi
Examining policy cohesion for cervical cancer worldwide: analysis of WHO country reports
ESMO Open 2020cited by 7position: middledoi
Evaluating triptorelin as a treatment option for breast cancer
Expert Opinion on Pharmacotherapy 2019cited by 5position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Giuseppe Curigliano · Istituti di Ricovero e Cura a Carattere Scientifico15 papers (2019–2025)Roberta Scafetta · Università Campus Bio-Medico8 papers (2023–2025)Antonio Marra · University of Milan6 papers (2020–2025)Carmen Criscitiello · Humanitas University6 papers (2023–2025) · 6 papers (2023–2025) · 4 papers (2023–2024) · 4 papers (2023–2024) · 4 papers (2023–2025)Liliana Ascione · Harvard University4 papers (2023–2024)Paola Zagami · European Institute of Oncology4 papers (2023–2025) · 4 papers (2024–2025)Elisabetta Munzone · Istituti di Ricovero e Cura a Carattere Scientifico3 papers (2024–2025) · 3 papers (2024–2024)Harold J. Burstein · Harvard University3 papers (2021–2024) · 3 papers (2023–2024)Manju Sengar · Grant Medical Center3 papers (2023–2025) · 3 papers (2024–2024)Carmen Belli · European Institute of Oncology3 papers (2020–2024) · 3 papers (2024–2025) · 3 papers (2024–2025)